Gilead Says New Hepatitis Drug Does Not Infringe Merck IP

Law360, New York (September 3, 2013, 3:26 PM EDT) -- Gilead Sciences Inc. has asked a federal court in California to issue a declaratory judgment that its hepatitis C drug would not infringe two Merck & Co. Inc. patents, or to deem the patents invalid, according to a suit filed Friday.

Foster City, Calif.-based Gilead said it has received calls and an email from Merck offering to license the rights to the two patents covering Merck's Victrelis hepatitis C drug for an allegedly untenable amount, in an attempt to prevent Gilead's competing medication from hitting the market.

The biopharmaceutical company, which said it specializes in developing treatments for life-threatening diseases such...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!